Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
Authors:
Open Access
- 18 September 2013
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 2 (5) , 674-686
Abstract
Up to 50% of patients with uveal melanoma develop metastatic disease with poor prognosis. Regional, mainly liver‐directed, therapies may induce limited tumor responses but do not improve overall survival. Response rates of metastatic uveal melanoma (MUM) to systemic chemotherapy are poor. Insights into the molecular biology of MUM recently led to investigation of new drugs. In this study, to compare response rates of systemic treatment for MUM we searched Pubmed/Web of Knowledge databases and ASCO website (1980–2013) for “metastatic/uveal/melanoma” and “melanoma/eye.” Forty studies (one case series, three phase I, five pilot, 22 nonrandomized, and two randomized phase II, one randomized phase III study, data of three expanded access programs, three retrospective studies) with 841 evaluable patients were included in the numeric outcome analysis. Complete or partial remissions were observed in 39/841 patients (overall response rate [ORR] 4.6%; 95% confidence intervals [CI] 3.3–6.3%), no responses were observed in 22/40 studies. Progression‐free survival ranged from 1.8 to 7.2, median overall survival from 5.2 to 19.0 months as reported in 21/40 and 26/40 studies, respectively. Best responses were seen for chemoimmunotherapy (ORR 10.3%; 95% CI 4.8–18.7%) though mainly in first‐line patients. Immunotherapy with ipilimumab, antiangiogenetic approaches, and kinase inhibitors have not yet proven to be superior to chemotherapy. MEK inhibitors are currently investigated in a phase II trial with promising preliminary data. Despite new insights into genetic and molecular background of MUM, satisfying systemic treatment approaches are currently lacking. Study results of innovative treatment strategies are urgently awaited.Keywords
Funding Information
- German Research Foundation
- University of Würzburg
This publication has 78 references indexed in Scilit:
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced MelanomaClinical Cancer Research, 2012
- Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal MelanomaClinical Cancer Research, 2012
- Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal OriginClinical Cancer Research, 2011
- Treatment implications of the emerging molecular classification system for melanomaThe Lancet Oncology, 2011
- Gene Regulatory and Clinical Effects of Interferon β in Patients with Metastatic Melanoma: A Phase II TrialJournal of Interferon & Cytokine Research, 2011
- Mutations inGNA11in Uveal MelanomaNew England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Long-term survival of uveal melanoma patients after surgery for liver metastasesBritish Journal of Ophthalmology, 2009
- PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In VitroInvestigative Ophthalmology & Visual Science, 2008
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000